BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32279388)

  • 21. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
    Xu J; Ji L; Liang Y; Wan Z; Zheng W; Song X; Gorshkov K; Sun Q; Lin H; Zheng X; Chen J; Jin RA; Liang X; Cai X
    Signal Transduct Target Ther; 2020 Dec; 5(1):298. PubMed ID: 33361760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
    Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
    J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
    Sun T; Mao W; Peng H; Wang Q; Jiao L
    Cell Oncol (Dordr); 2021 Jun; 44(3):689-699. PubMed ID: 33655469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
    Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
    Shao Z; Li Y; Dai W; Jia H; Zhang Y; Jiang Q; Chai Y; Li X; Sun H; Yang R; Cao Y; Feng F; Guo Y
    Pharmacol Res; 2018 Sep; 135():188-200. PubMed ID: 30114438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma.
    Zhang S; Gao W; Tang J; Zhang H; Zhou Y; Liu J; Chen K; Liu F; Li W; To SKY; Wong AST; Zhang XK; Zhou H; Zeng JZ
    Theranostics; 2020; 10(3):1230-1244. PubMed ID: 31938062
    [No Abstract]   [Full Text] [Related]  

  • 30. RNA m
    Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
    EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
    Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
    Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
    J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy.
    Li J; Wu PW; Zhou Y; Dai B; Zhang PF; Zhang YH; Liu Y; Shi XL
    Cell Death Dis; 2018 Feb; 9(2):225. PubMed ID: 29445087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
    Al-Abdulla R; Lozano E; Macias RIR; Monte MJ; Briz O; O'Rourke CJ; Serrano MA; Banales JM; Avila MA; Martinez-Chantar ML; Geier A; Andersen JB; Marin JJG
    Br J Pharmacol; 2019 Mar; 176(6):787-800. PubMed ID: 30592786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
    Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
    Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
    Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
    Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-HB treatment reverses sorafenib resistance by shifting glycolysis-lactate metabolism in HCC.
    Suk FM; Wu CY; Fang CC; Chen TL; Liao YJ
    Biomed Pharmacother; 2023 Oct; 166():115293. PubMed ID: 37567069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Blivet-Van Eggelpoël MJ; Chettouh H; Fartoux L; Aoudjehane L; Barbu V; Rey C; Priam S; Housset C; Rosmorduc O; Desbois-Mouthon C
    J Hepatol; 2012 Jul; 57(1):108-15. PubMed ID: 22414764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance.
    Zhao W; Ma B; Tian Z; Han H; Tang J; Dong B; An G; Cao B; Wang B
    Br J Cancer; 2021 Mar; 124(7):1237-1248. PubMed ID: 33473171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.